International Clinical Trial: A Multicenter, Prospective, Single-Arm Clinical Study of Venetoclax Combined with Chidamide (Tucidinostat) and Chiglitazar Sodium (VCC Regimen) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134957) titled 'A Multicenter, Prospective, Single-Arm Clinical Study of Venetoclax Combined with Chidamide (Tucidinostat) and Chiglitazar Sodium (VCC Regimen) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)' on Oct. 22.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Xiamen University

Condition: Relapsed or Refractory Acute myeloid leukemia

Intervention: Intervention group:Venetoclax, cidabene amide in combination with sitagliptin sodium: Cediranib: 30 mg per dose, twice a week, for 2 weeks Venetoclax: 200 mg per dose, once a day, for 2 we...